

ROBUST PIPELINE OF SWITCH-CONTROL KINASE INHIBITORS

		RESEARCH	IND-ENABLING	PHASE 1	PHASE 1/2	PHASE 3	REGULATORY SUBMISSION	APPROVED
QINLOCK¹ (ripretinib) 50mg tablets KIT Inhibitor	GIST ≥4 th Line	[Progress bar spanning RESEARCH to PHASE 3]						+ Global Approvals ³
	GIST 2 nd Line KIT Exon 11 + 17/18 (INSIGHT Phase 3 Study) ²	[Progress bar spanning RESEARCH to PHASE 1/2]						
Vimseltinib CSF1R Inhibitor	TGCT (MOTION Phase 3 Study)	[Progress bar spanning RESEARCH to PHASE 3]						
	TGCT (Phase 1/2 Study)	[Progress bar spanning RESEARCH to PHASE 1/2]						
DCC-3116 ULK Inhibitor	+ MEK Inhibitors (Trametinib or Binimetinib)	[Progress bar spanning RESEARCH to PHASE 1]						
	+ KRAS ^{G12C} Inhibitor (Sotorasib)	[Progress bar spanning RESEARCH to PHASE 1]						
	+ BRAF inhibitor / EGFR inhibitor (Encorafenib / Cetuximab)	[Progress bar spanning RESEARCH to PHASE 1]						
	+ KIT Inhibitor (QINLOCK)	[Progress bar spanning RESEARCH to PHASE 1]						
DCC-3084 Pan-RAF Inhibitor	Solid Tumors and Hematologic Malignancies	[Planned for 4Q 2023 ⁴]						
DCC-3009 Pan-KIT Inhibitor	GIST	[Planned for 1H 2024]						
Additional Programs	GCN2	[Progress bar spanning RESEARCH to PHASE 1]						
	VPS34 ⁵	[Progress bar spanning RESEARCH to PHASE 1]						



Notes: BRAF=proto-oncogene b-RAF; CSF1R=colony-stimulating factor 1 receptor; EGFR=epidermal growth factor receptor; GCN2=general control nonderepressible 2; GIST=gastrointestinal stromal tumor; KIT=KIT proto-oncogene receptor tyrosine kinase; MAPK=mitogen-activated protein kinase; RAF=rapidly accelerated fibrosarcoma; RAS=rat sarcoma gene; TGCT=tenosynovial giant cell tumor; ULK=unc-51-like autophagy-activating kinase; (1) Exclusive development and commercialization license with Zai Lab in Greater China for QINLOCK; (2) The patient population for the INSIGHT study consists of second-line GIST patients with mutations in KIT exon 11 and 17 and/or 18 and the absence of mutations in KIT exon 9, 13, and/or 14 (also referred to as KIT exon 11 + 17/18 patients); (3) QINLOCK is approved for 4th line GIST in the Australia, Canada, China, the European Union, Hong Kong, Israel, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States; (4) 2023 Corporate Goal; (5) Agreement with Sprint Bioscience for exclusive in-license worldwide rights to a research-stage program targeting VPS34.